The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35249
Mayo Clinic- Scottsdale, Scottsdale, Arizona, United States, 85259
University of California Irvine - Manchester Pavilion, Orange, California, United States, 92868
University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center), Aurora, Colorado, United States, 80045
Medstar Georgetown University Hospital, Washington, District of Columbia, United States, 20007
University of Florida College of Medicine Gainesville; Neurology, Gainesville, Florida, United States, 32608
Nemours Children's Clinic - of the Nemours Foundation, Jacksonville, Florida, United States, 32207
Meridian Clinical Research, LLC, Savannah, Georgia, United States, 31406
Northwestern University, Chicago, Illinois, United States, 60611
Consultants in Neurology Ltd, Northbrook, Illinois, United States, 60062
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to
ALL
No
Hoffmann-La Roche,
Clinical Trials, STUDY_DIRECTOR, Hoffmann-La Roche
2028-12-31